In the 1970s, an unknown virus was suspected for documented cases of transfusion-
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …

Hepatitis C virus (HCV) is a hepatotropic RNA virus that causes progressive liver damage,
which might result in liver cirrhosis and hepatocellular carcinoma. Globally, between 64 and …

Importance Hepatitis C virus (HCV) infects more than 185 million individuals worldwide.
Twenty percent of patients chronically infected with HCV progress to cirrhosis. New, simpler …

The hepatitis C virus (HCV) was discovered in the late 1980s. Interferon (IFN)-α was
proposed as an antiviral treatment for chronic hepatitis C at about the same time. Successive …

Protein and peptide drugs hold great promise as therapeutic agents. However, many are
degraded by proteolytic enzymes, can be rapidly cleared by the kidneys, generate …

Background Treatment with peginterferon alfa-2a alone produces significantly higher
sustained virologic responses than treatment with interferon alfa-2a alone in patients with …

Background A sustained virological response (SVR) rate of 41% has been achieved with
interferon alfa-2b plus ribavirin therapy of chronic hepatitis C. In this randomised trial …

Hepatitis C virus (HCV) infects an estimated 170 million persons worldwide and thus
represents a viral pandemic, one that is five times as widespread as infection with the …

Background: Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks
is more effective than conventional interferon and ribavirin in patients with chronic hepatitis …

Viral infections cause many serious human diseases with high mortality rates. New drug‐
resistant strains are continually emerging due to the high viral mutation rate, which makes it …